| Medical and Health Sciences | 2021-2025 | 79 | CH 1 | 99.98 |
| Pulmonary and Respiratory Medicine | Lifetime | 94 | CH 2 | 99.87 |
| Oncology | Lifetime | 106 | CH 2 | 99.82 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 10 | CH 1 | 99.97 |
| Oncology | 2021-2025 | 6 | CH 1 | 99.97 |
| Cancer Research | 2021-2025 | 100 | CH 1 | 95.40 |
| Immunology | 2021-2025 | 336 | CH 9 | 91.33 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 28 | CH 1 | 99.82 |
| Lung Cancer Treatments and Mutations | Lifetime | 39 | CH 1 | 99.88 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 52 | CH 2 | 99.84 |
| Lung Cancer Research Studies | Lifetime | 32 | CH 1 | 99.80 |
| COVID-19 and healthcare impacts | Lifetime | 27 | CH 1 | 99.13 |
| Cancer Genomics and Diagnostics | Lifetime | 391 | CH 4 | 99.26 |
| Colorectal Cancer Treatments and Studies | Lifetime | 316 | CH 5 | 99.01 |
| Peptidase Inhibition and Analysis | Lifetime | 589 | CH 10 | 97.99 |
| Cancer therapeutics and mechanisms | Lifetime | 443 | CH 4 | 97.69 |
| HER2/EGFR in Cancer Research | Lifetime | 605 | CH 9 | 97.57 |
| Advances in Oncology and Radiotherapy | Lifetime | 254 | CH 2 | 94.80 |
| Brain Metastases and Treatment | Lifetime | 604 | CH 16 | 96.37 |
| Cancer Mechanisms and Therapy | Lifetime | 626 | CH 5 | 94.19 |
| Occupational and environmental lung diseases | Lifetime | 650 | CH 7 | 94.22 |
| Pleural and Pulmonary Diseases | Lifetime | 989 | CH 17 | 93.53 |
| Economic and Financial Impacts of Cancer | Lifetime | 913 | CH 9 | 92.17 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 6 | CH 1 | 99.97 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 5 | CH 1 | 99.87 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 7 | CH 1 | 99.96 |
| Lung Cancer Research Studies | 2021-2025 | 9 | CH 1 | 99.91 |
| Cancer Genomics and Diagnostics | 2021-2025 | 46 | CH 1 | 99.54 |
| COVID-19 and healthcare impacts | 2021-2025 | 105 | CH 2 | 97.40 |
| Occupational and environmental lung diseases | 2021-2025 | 25 | CH 2 | 97.23 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 113 | CH 1 | 98.44 |
| Immunotherapy and Immune Responses | 2021-2025 | 208 | CH 9 | 96.93 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 263 | CH 6 | 95.45 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 812 | CH 7 | 94.44 |
| Immune cells in cancer | 2021-2025 | 575 | CH 10 | 91.22 |
| Brain Metastases and Treatment | 2021-2025 | 341 | CH 10 | 91.53 |
| Cancer therapeutics and mechanisms | 2021-2025 | 212 | CH 2 | 88.58 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 591 | CH 10 | 90.30 |
| Pleural and Pulmonary Diseases | 2021-2025 | 282 | CH 8 | 86.42 |
| HER2/EGFR in Cancer Research | 2021-2025 | 656 | CH 5 | 89.53 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 532 | CH 6 | 87.71 |
| Cancer Diagnosis and Treatment | 2021-2025 | 602 | CH 6 | 79.20 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 564 | CH 18 | 80.67 |
| Advances in Oncology and Radiotherapy | 2021-2025 | 491 | CH 5 | 78.79 |
